Javier Rejas Gutiérrez-rekin lankidetzan egindako argitalpenak (8)

2019

  1. Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 19, Núm. 1, pp. 45-57

2018

  1. Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex

    Neurologia, Vol. 33, Núm. 3, pp. 141-153

  2. Cost of treating peripheral neuropathic pain with pregabalin or gabapentin at therapeutic doses in routine practice

    Journal of Comparative Effectiveness Research, Vol. 7, Núm. 7, pp. 615-625

2017

  1. Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity

    Journal of Evaluation in Clinical Practice, Vol. 23, Núm. 2, pp. 402-412

2015

  1. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice

    Drug Design, Development and Therapy, Vol. 9, pp. 4329-4340

2013

  1. Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain

    Pain Medicine (United States), Vol. 14, Núm. 12, pp. 1954-1963

2011

  1. Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use

    European Addiction Research, Vol. 17, Núm. 5, pp. 262-270

2005

  1. Prevalencia del dolor neuropático en España: Implicaciones clínicas, laborales y asistenciales

    Medicina Clinica, Vol. 125, Núm. 6, pp. 221-229